|
Good day, 360! |
Here are our top 3 investing ideas today. These setups look primed! And be sure to vote in our new poll at the bottom. Let us know what you think! |
|
|
LMDX - Up over 150% in pre-market after partnership with AstraZenica for England's first heart and lung screening hub |
ACON - Up over 9% in pre after signing letter of intent with ATEC to advance the commercialization of Nociscan |
HARP - Up over 13% pre after announcing 35% response rate in Phase 1 / 2 small cell lung cancer clinical trial |
|
|
Would you agree? The market has been an oppressive tyrant for a while now – but Jeff Bishop and his loyal subscribers are not rolling over. They've been fighting arm and arm out of that terrible September! It looks just like this: | | And then THIS: | | Jeff has already OBLITERATED his $10,000 goal this month in Alpha Hunter in true William Wallace fashion ⚔️ → You can check his stats here! | And dropping minutes from now is Jeff's next pick of the week 🎯in Bullseye Trades. Last week's Bullseye (betting against NVDA) could have netted you 300% – were you in? If not… | Get in HERE NOW, join Jeff for his LIVE breakdown 11AM EST Mondays and… CHARGE 🪓⚔️🛡️ |
|
|
|
|
LMDX - Up over 150% in pre-market after announcing partnership with AstraZenica for England's first heart and lung screening hub |
LumiraDx (LMDX) operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. |
Late Friday in the after-hours, the company announced a partnership with AstraZeneca and Everton in the Community (the official charity of Everton Football Club) to set up England's first heart and lung screening hub. |
The LumiraDx NT-proBNP test is the only NT-proBNP test currently available that can be used with a simple fingerstick sample. |
Covering multiple clinical areas, the LumiraDx Platform is also ideally placed for lung-related health checks and other cardiometabolic disease screening, offering HbA1c, CRP, D-Dimer, Influenza A/B, RSV & SARS-CoV-2 Antigen Tests; all on a single Platform. |
The stock traded up over 150% in the pre-market after the press release. |
|
The $0.24 area was a level of resistance in the after-hours and now become a potential area of support. |
Above it, targets to the upside are $0.30, $0.40, $0.50 and $0.60. Beyond that, $0.80, $0.90 and $1 come into play. |
Below $0.24, there is potential support at $0.23, $0.21, $0.20, $0.15, $0.12 and a gap fill at $0.0892. |
|
ACON - Up over 9% after signing letter of intent with ATEC to advance the commercialization of Nociscan |
Aclarion (ACON), a healthcare technology company that leverages for Magnetic Resonance Spectroscopy (MRS) in the United States dedicated to revolutionizing the approach to spine surgery. |
This morning, the company announced that it had signed a strategic partnership letter of intent (LOI) with ATEC to advance the commercialization of Nociscan. |
The partnership aims to include Aclarion's Nociscan surgical decisioning technology within ATEC's AlphaInformatiX platform to better inform spine surgery. |
The stock traded up over 9% in pre-market after the news. |
|
$0.60 has acted as a support level in the pre-market. |
Above it, targets to the upside are $0.70, $0.73 and then the pre-market high at $0.85. Beyond that, $1 and $1.20 come into play. |
Below $0.60, there is a gap to fill at $0.5650 and then $0.50 comes into play. |
|
HARP - Up over 13% pre after announcing 35% response rate in Phase 1 / 2 small cell lung cancer clinical trial |
Harpoon Therapeutics (HARP) is a clinical-stage immunotherapy company that engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. |
Over the weekend, the company announced that it had achieved a confirmed response rate 35% (11/31), across all tumor types and patient cohorts treated with 1 mg priming dose, including three confirmed, complete responses in phase 1/2 clinical trial of t cell engager hpn328 evaluating HPN328 in small cell lung cancer (SCLC) and other neuroendocrine tumor types in a poster at the European Society of Medical Oncology Congress (ESMO) 2023. |
HARP is now on track to select Phase 2 dose(s) by end of 2023. |
The stock traded over 13% higher in pre-market on the news and the company also announced a $150 million private placement. |
|
|
HARP found buyers on the pre-market at $9 and that level now becomes a potential area of resistance. |
Above it, targets to the upside are $10, $11 and then the pre-market high at $12.90. |
Below $9, there is potential support at $7.40 and then a gap to fill at $6.88. |
|
|
Economic Calendar |
|
|
Poll: The market was down big last week, this week it's time to: |
|
|
|
Questions or concerns about our products? Email Support@360wallstreet.io © Copyright 2022, RagingBull |
|
|
DISCLAIMER To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at https://ragingbull.com/disclaimer |
|
|
FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. |
|
|
RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. |
|
|
RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. |
|
|
RagingBull.com, LLC shall be entitled to recover attorneys' fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys' fees, costs and disbursements in addition to any other relief to which it may be entitled. |
|
|
WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. |
|
|
|
Post a Comment
Post a Comment